ASCO GI 2024: Radioligand Therapy for Gastroenteropancreatic Neuroendocrine Tumors
Posted: 01/31/2024 | By: Chase Doyle

The phase III NETTER-2 study evaluated Lu-177 dotatate as first-line treatment in patients with grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors. Results were presented at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract LBA588).

Question 1 of 5

What does lutetium Lu-177 dotatate (Lu-177 dotatate) target in gastroenteropancreatic neuroendocrine tumors?

Choose 1